Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international ...

Moderna stock is soaring. Is it too late to buy?

Moderna's full pipeline may fuel long-term growth.
Zacks.com on MSN

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

Moderna (MRNA) ended the recent trading session at $51.30, demonstrating a -1.54% change from the preceding day's closing price. This change lagged the S&P 500's 0.62% gain on the day. Meanwhile, the ...

You'll never guess which healthcare stock delivered the best first-quarter performance in the S&P 500

Could this player be heading into a new era of growth?

2 Healthcare Stocks That Could Soar Over the Next 5 Years

They could make important breakthroughs in their target markets.
Nasdaq

Why Moderna Stock Just Popped

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...

MRNY: Strong Income Run Masks Rising Downside Risk

YieldMax MRNA Option Income Strategy ETF is rated a Sell due to heightened downside risk and overvalued pipeline optimism.